ENANTA PHARMACEUTICALS, INC Operating Lease, Liability, Noncurrent
ENANTA PHARMACEUTICALS, INC (ENTA) had Operating Lease, Liability, Noncurrent of $51.75 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-12
- 2026-06-30: Operating Lease, Liability, Noncurrent $51.75M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $52.78M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $53.78M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $54.76M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $51.75M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $52.78M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $53.78M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $54.76M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $55.66M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $56.54M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $56.45M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $53.94M 10-K · filed 2025-11-19 |
| 2024-06-30 | $48.14M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $43.41M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $20.52M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $21.24M 10-K · filed 2024-11-27 |
| 2023-06-30 | $22.33M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $23.07M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $21.86M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $22.37M 10-K · filed 2023-11-22 |
| 2022-06-30 | $22.21M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $15.12M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $15.96M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $1.13M 10-K · filed 2022-11-23 |
| 2021-06-30 | $1.64M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.64M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $3.52M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $3.84M 10-K · filed 2021-11-24 |
| 2020-06-30 | $4.55M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $5.33M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $5.99M 10-Q · filed 2020-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |